-
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 Leukemia (IF 11.4) Pub Date : 2024-05-15 Diletta Fontana, Federica Malighetti, Matteo Villa, Alfonso Zambon, Carlo Gambacorti-Passerini, Luca Mologni
-
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis Leukemia (IF 11.4) Pub Date : 2024-05-15 Trent P. Wang, Kwang W. Ahn, Mazyar Shadman, Manmeet Kaur, Nausheen Ahmed, Ulrike Bacher, Jan Cerny, Andy Chen, Narendranath Epperla, Matthew Frigault, Natalie Grover, Bradley Haverkos, Brian Hill, Nasheed Hossain, Madiha Iqbal, Tania Jain, Maxwell M. Krem, Joseph Maakaron, Dipenkumar Modi, Muhamad Alhaj Moustafa, Peter Riedell, Bipin Savani, R. Alejandro Sica, Anna Sureda, Kitsada Wudhikarn, Alex
-
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma Leukemia (IF 11.4) Pub Date : 2024-05-15 Jin-Hua Liang, Yi-Fan Wu, Hao-Rui Shen, Yue Li, Jun-Heng Liang, Rui Gao, Wei Hua, Chun-Yu Shang, Kai-Xin Du, Tong-Yao Xing, Xin-Yu Zhang, Chen-Xuan Wang, Liu-Qing Zhu, Yang W. Shao, Jian-Yong Li, Jia-Zhu Wu, Hua Yin, Li Wang, Wei Xu
-
The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients Blood Cancer J. (IF 12.8) Pub Date : 2024-05-14 Jie Tian, Yongmei Zhu, Jianfeng Li, Guang Yang, Xiangqin Weng, Ting Huang, Lingling Zhao, Haimin Sun, Zeying Yan, Sujiang Zhang
-
Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-14 Nico Gagelmann, Claudia Schuh, Sarah Flossdorf, Desiree Kunadt, Matthias Stelljes, Igor W. Blau, Arne Brecht, Wolfgang Bethge, Thomas Schroeder, Gerald Wulf, Elisa Sala, Gesine Bug, Katharina Fleischhauer, Nicolaus Kröger
One key aspect of allogeneic hematopoietic cell transplantation (HCT) is pretransplant conditioning, balancing risk for relapse versus non-relapse mortality. Conditioning regimens with different alkylators at different doses can influence outcome, but data are missing for myelofibrosis, a challenging cohort of patients usually presenting at older age and with comorbidities. We evaluated in a multicenter
-
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols Leukemia (IF 11.4) Pub Date : 2024-05-14 Martin Neumann, Thomas Beder, Lorenz Bastian, Sonja Hänzelmann, Miriam Bultmann, Nadine Wolgast, Alina Hartmann, Heiko Trautmann, Jutta Ortiz-Tanchez, Cornelia Schlee, Michael Schroeder, Lars Fransecky, Sebastian Vosberg, Walter Fiedler, Nael Alakel, Lisa Heberling, Mustafa Kondakci, Michael Starck, Stefan Schwartz, Simon Raffel, Carsten Müller-Tidow, Folker Schneller, Albrecht Reichle, Thomas Burmeister
-
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines Leukemia (IF 11.4) Pub Date : 2024-05-14 Vincent H. J. van der Velden, Isabel Dombrink, Julia Alten, Giovanni Cazzaniga, Emmanuelle Clappier, Daniela Drandi, Cornelia Eckert, Eva Fronkova, Jeremy Hancock, Michaela Kotrova, Rebekka Kraemer, Mirkka Montonen, Heike Pfeifer, Christiane Pott, Thorsten Raff, Heiko Trautmann, Hélène Cavé, Beat W. Schäfer, Jacques J. M. van Dongen, Jan Trka, Monika Brüggemann
-
Critical role of the gut microbiota in immune responses and cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-05-14 Zehua Li, Weixi Xiong, Zhu Liang, Jinyu Wang, Ziyi Zeng, Damian Kołat, Xi Li, Dong Zhou, Xuewen Xu, Linyong Zhao
The gut microbiota plays a critical role in the progression of human diseases, especially cancer. In recent decades, there has been accumulating evidence of the connections between the gut microbiota and cancer immunotherapy. Therefore, understanding the functional role of the gut microbiota in regulating immune responses to cancer immunotherapy is crucial for developing precision medicine. In this
-
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis Blood Cancer J. (IF 12.8) Pub Date : 2024-05-14 Yoonkyu Lee, Linda B. Baughn, Chad L. Myers, Zohar Sachs
-
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects” Blood Cancer J. (IF 12.8) Pub Date : 2024-05-14 Joji Nagasaki, Mitsutaka Nishimoto, Hideo Koh, Hiroshi Okamura, Mika Nakamae, Kazuki Sakatoku, Kentaro Ido, Masatomo Kuno, Yosuke Makuuchi, Teruhito Takakuwa, Yasuhiro Nakashima, Masayuki Hino, Hirohisa Nakamae
-
Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-14 M. Michel, M. Saïr, E. Rivière, G. Moulis, T. Comont, N. Costedoat‐Chalumeau, C. Pouchelon, D. Boutboul, A. Benyamine, A. Bert, P. ‐Y. Jeandel, S. Hamrouni, N. Belfeki, H. Lobbes, A. Dossier, D. Gobert, M. Mahevas, B. Godeau, Y. Gallien, M. Ebbo
Adult autoimmune hemolytic anemia (AIHA) is a rare but potentially life-threatening acquired autoimmune disease in which autoantibodies directed toward antigens of autologous red blood cells (RBC) membrane lead to their accelerated destruction. Corticosteroids are the cornerstone first-line therapy for primary warm AIHA (wAIHA) and rituximab is commonly used off-label as a second-line option in most
-
Integrated proteogenomic analysis for inherited bone marrow failure syndrome Leukemia (IF 11.4) Pub Date : 2024-05-13 Manabu Wakamatsu, Hideki Muramatsu, Hironori Sato, Masaki Ishikawa, Ryo Konno, Daisuke Nakajima, Motoharu Hamada, Yusuke Okuno, Yusuke Kawashima, Asahito Hama, Masafumi Ito, Hideto Iwafuchi, Yoshiyuki Takahashi, Osamu Ohara
-
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-05-11 Nicholas J. Short, Elias Jabbour, Nitin Jain, Hagop Kantarjian
Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval
-
DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients Leukemia (IF 11.4) Pub Date : 2024-05-11 Adam Karami, Tomasz Skorski
-
Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis Leukemia (IF 11.4) Pub Date : 2024-05-11 Hussein Awada, Arda Durmaz, Tariq Kewan, Fauzia Ullah, Danai Dima, Hassan Awada, Simona Pagliuca, Manja Meggendorfer, Torsten Haferlach, Carmelo Gurnari, Valeria Visconte, Jaroslaw P. Maciejewski
-
TIF1β activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia Leukemia (IF 11.4) Pub Date : 2024-05-11 Mariko Morii, Sho Kubota, Mihoko Iimori, Takako Yokomizo-Nakano, Ai Hamashima, Jie Bai, Akiho Nishimura, Masayoshi Tasaki, Yukio Ando, Kimi Araki, Goro Sashida
-
Cost‐effectiveness of sutimlimab in cold agglutinin disease Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-11 Satoko Ito, Daniel Wang, Adriana Purcell, Karthik Chetlapalli, Alfred I. Lee, Adam Cuker, George Goshua
-
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-11 Elisabeth Dovern, Mesire Aydin, Mette D. Hazenberg, Man Wai Tang, Elisabeth M. Suijk, Gerianne M. Hoogendoorn, Charlotte F. J. Van Tuijn, Jean‐Louis Kerkhoffs, Caroline E. Rutten, Sacha S. Zeerleder, Josu de la Fuente, Bart J. Biemond, Erfan Nur
-
Genomic landscape of CCUS compared to MDS and its implications on risk prediction Leukemia (IF 11.4) Pub Date : 2024-05-10 Sandra Huber, Constance Baer, Stephan Hutter, Natalie Wossidlo, Gregor Hoermann, Christian Pohlkamp, Wencke Walter, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
-
PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL Leukemia (IF 11.4) Pub Date : 2024-05-09 Mustafa Farhat, Wayne Croft, Helen M. Parry, Kriti Verma, Francesca A. M. Kinsella, Jinsong Xu, David Bone, Tina McSkeane, Shankara Paneesha, Guy Pratt, Paul Moss, Jianmin Zuo
-
AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML Leukemia (IF 11.4) Pub Date : 2024-05-09 Ece Canan Sayitoglu, Bogdan A. Luca, Allison Paige Boss, Benjamin Craig Thomas, Robert Arthur Freeborn, Molly Javier Uyeda, Pauline Ping Chen, Yusuke Nakauchi, Colin Waichler, Norman Lacayo, Rosa Bacchetta, Ravindra Majeti, Andrew J. Gentles, Alma-Martina Cepika, Maria Grazia Roncarolo
-
Clinical and biological characterization of involvement of nasal‐associated lymphoid tissues in chronic lymphocytic leukemia Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-10 Thimali Ranaweera Arachchige, Catherine Mendiburu, Antoine Martin, Carole Fleury, Elisabetta Dondi, Rémi Letestu, Virginie Eclache, Fanny Baran‐Marszak, Florence Cymbalista, Gregory Lazarian
Patients with chronic lymphocytic leukemia (CLL) are prone to infectious complications, including ear, nose, and throat (ENT) infections, due to humoral immunodepression and/or immunosuppression related to therapy. However, specific CLL infiltration in nonlymphoid regions of the head and neck causing ENT symptoms but unrelated to an infection has not been described. CLL is a disease of lymphoid organs
-
Ponatinib‐review of historical development, current status, and future research Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-10 Hagop M. Kantarjian, Helen T. Chifotides, Fadi G. Haddad, Nicholas J. Short, Sanam Loghavi, Elias Jabbour
Ponatinib is a third‐generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with high potency against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated disease, which is resistant to first‐ and second‐generation TKIs. Ponatinib was approved for T315I‐mutated chronic myeloid leukemia (CML), CML resistant/intolerant to ≥2 prior TKIs, advanced phase CML and Ph‐positive acute lymphoblastic
-
Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD Leukemia (IF 11.4) Pub Date : 2024-05-08 Min Yang, Zhiyuan Ma, Chonggang Wang, Muammer Cihan Agca, Hongyun Liu, Kezhi Huang, Silke Glage, Regina Rumpel, Alexander Gerbaulet, Axel Roers, Xuemei Liu, Fatih Noyan, Nils von Neuhoff, Arnold Ganser, Ligen Liu, Haiyang Yun, Zhixiong Li
-
A case of familial donor-derived acute myeloid leukemia with underlying pre-leukemic mutations. Haematologica (IF 10.1) Pub Date : 2024-05-09 Luca Vincenzo Cappelli, Clara Minotti, Manja Meggendorfer, Marietta Truger, Torsten Haferlach, Cristina Mecucci, Caterina Matteucci, Caterina Alati, Anna Paola Iori, Maurizio Martelli, Robin Foà
Not available.
-
The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans. Haematologica (IF 10.1) Pub Date : 2024-05-09 Tereza Faitova, Mariana Coelho, Caspar Da Cunha-Bang, Selcen Ozturk, Ece Kartal, Peer Bork, Martina Seiffert, Carsten U Niemann
The gut microbiota play a critical role in maintaining a healthy human body and their dysregulation is associated with various diseases. In this study, we investigated the influence of the gut microbiome diversity on chronic lymphocytic leukemia (CLL) development. Stool sample analysis of 59 CLL patients revealed individual and heterogeneous microbiome compositions, but allowed for grouping of patients
-
HES6: an emerging player in human hematopoiesis. Haematologica (IF 10.1) Pub Date : 2024-05-09 Jian Xu, Wei Du
Not available.
-
Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol. Haematologica (IF 10.1) Pub Date : 2024-05-09 Bernward Zeller, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Jose M Fernandez Navarro, Henrik Hasle, Kirsi Jahnukainen, Kristian Lovvik Juul-Dam, Gertjan Kaspers, Zanna Kovalova, Olafur G Jonsson, Birgitte Lausen, Monica Munthe-Kaas, Ulrika Noren Nystrom, Josefine Palle, Ramune Pasauliene, Cornelis J Pronk, Kadri Saks, Anne Tierens, Jonas Abrahamsson
Hyperleukocytosis (HL) in pediatric acute myeloid leukemia (AML) is associated with severe complications and inferior outcome. We report results on HL patients included in the NOPHO-DBH AML 2012 study. We recommended immediate start of full dose chemotherapy (etoposide [ETO] monotherapy for 5 days as part of the first course), avoiding leukapheresis (LA) and prephase chemotherapy (PCT). Of 714 included
-
The insertion/deletion polymorphism rs201494641 at ITGA9 influences blood CD34+ cell levels by altering ZNF384 binding. Haematologica (IF 10.1) Pub Date : 2024-05-09 Caterina Cafaro, Zain Ali, Antton Lamarca, Daniela Torres Di Bello, Laura Duran Lozano, Ludvig Ekdahl, Malte Thodberg, Maroulio Pertesi, Aitzkoa Lopez De Lapuente Portilla, Björn Nilsson
Not available.
-
Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study. Haematologica (IF 10.1) Pub Date : 2024-05-09 Lisa V E Oostenbrink, Erik G J Von Asmuth, Cornelia M Jol-van der Zijde, Anja M Jansen-Hoogendijk, Carly Vervat, Robbert G M Bredius, Maarten J D Van Tol, Marco W Schilham, Petr Sedlacek, Marianne Ifversen, Adriana Balduzzi, Peter Bader, Christina Peters, Dirk Jan A R Moes, Arjan C Lankester
Anti T-lymphocyte globulin (ATLG) is used in hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host disease (GvHD) and graft failure. To date, insight in ATLG pharmacokinetics and -dynamics (PK/PD) is limited, and population PK (POPPK) models are lacking. In this prospective study, we describe ATLG POPPK using NONMEM® and the impact of ATLG exposure on clinical outcome and immune
-
Cachexia during anti-leukemia chemotherapy: it is not "just" the chemo. Haematologica (IF 10.1) Pub Date : 2024-05-09 Armin Rashidi
Not available.
-
From niche to blockbuster: a greater role for allopurinol in maintenance treatment of acute lymphoblastic leukemia. Haematologica (IF 10.1) Pub Date : 2024-05-09 Martin Stanulla
Not available.
-
Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy. Haematologica (IF 10.1) Pub Date : 2024-05-09 Chiara Tarantelli, David Wald, Nicolas Munz, Filippo Spriano, Alessio Bruscaggin, Eleonora Cannas, Luciano Cascione, Eugenio Gaudio, Alberto J Arribas, Shivaprasad Manjappa, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Giorgio Inghirami, Patrick H Van Berkel, Davide Rossi, Paolo F Caimi, Francesca Zammarchi, Francesco Bertoni
Antibody-drug conjugates (ADCs) represent one of the most successful therapeutic approaches introduced in clinical practice in the last few years. Loncastuximab tesirine (ADCT-402) is a CD19 targeting ADC, in which the antibody is conjugated through a protease cleavable dipeptide linker to a pyrrolobenzodiazepine (PBD) dimer warhead (SG3199). Based on the results of a phase 2 study, loncastuximab tesirine
-
Mental health and use of psychotropic prescription drugs in adult patients with primary immune thrombocytopenia: a nationwide population-based cohort study. Haematologica (IF 10.1) Pub Date : 2024-05-09 Nikolaj Mannering, Dennis Lund Hansen, Anton Pottegård, Kjeld Andersen, Henrik Frederiksen
Patients with primary immune thrombocytopenia (ITP) suffer from reduced survival and quality of life, but the underlying reasons for this are largely undescribed. Mental health and the use of psychotropic drugs in ITP is unknown. We investigated the risk of hospital registered mental health events including fatigue and the use of psychotropic drugs in adult patients with ITP compared with the general
-
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica (IF 10.1) Pub Date : 2024-05-09 Yoshiko Atsuta, Helen Baldomero, Daniel Neumann, Anna Sureda, Jakob D DeVos, Minako Iida, Amado Karduss, Duncan Purtill, Alaa M Elhaddad, Nosa G Bazuaye, Carmem Bonfim, Rafael De la Camara, Naeem A Chaudhri, Fabio Ciceri, Cinthya Correa, Cristobal Frutos, Sebastian Galeano, Laurent Garderet, Oscar Gonzalez-Ramella, Raffaella Greco, Nada Hamad, Mette D Hazenberg, Mary M Horowitz, Krzysztof Kalwak, Bor-Sheng
Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for Blood and Marrow Transplantation, a non-Governmental organization in working relations with the World Health Organization. HCT activities are recorded annually by member societies, national registries
-
A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report. Haematologica (IF 10.1) Pub Date : 2024-05-09 Francesca Elice, Roberta Sommaggio, Elisa Cappuzzello, Marcello Riva, Maria Chiara Tisi, Martina Bernardi, Angela Bozza, Daniela Catanzaro, Katia Chieregato, Anna Merlo, Ilaria Giaretta, Anna Dalla Pieta, Mauro Krampera, Carlo Visco, Livio Trentin, Andrea Visentin, Alberto Tosetto, Giuseppe Astori, Antonio Rosato
Not available.
-
Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose Leukemia (IF 11.4) Pub Date : 2024-05-07 Golda Gross, Suha Alkadieri, Amilia Meir, Orit Itzhaki, Yarden Aharoni-Tevet, Shahar Ben Yosef, Angi Zenab, Liat Shbiro, Amos Toren, Tal Yardeni, Elad Jacoby
-
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-05-08 Hao Lin, Chaxian Liu, Ankang Hu, Duanwu Zhang, Hui Yang, Ying Mao
Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and
-
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis Leukemia (IF 11.4) Pub Date : 2024-05-07 Fuhui Li, Tiejun Qin, Bing Li, Shiqiang Qu, Lijuan Pan, Peihong Zhang, Qi Sun, Wenyu Cai, Qingyan Gao, Meng Jiao, Junjie Li, Xiaofei Ai, Jiao Ma, Robert Peter Gale, Zefeng Xu, Zhijian Xiao
-
Small molecule inhibitors targeting m6A regulators J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-05-06 Guotai Feng, Yongya Wu, Yuan Hu, Wen Shuai, Xiao Yang, Yong Li, Liang Ouyang, Guan Wang
As the most common form of epigenetic regulation by RNA, N6 methyladenosine (m6A) modification is closely involved in physiological processes, such as growth and development, stem cell renewal and differentiation, and DNA damage response. Meanwhile, its aberrant expression in cancer tissues promotes the development of malignant tumors, as well as plays important roles in proliferation, metastasis,
-
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-05-06 Yun Kang, Chenggong Li, Heng Mei
Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as immediate accessibility for patients, stable quality due to industrialized manufacturing and additional
-
Correction to “Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy” Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-07
Lunning, MA, Wang, H, Hu, Z-H, et al. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024; 99(5): 880–889. doi:10.1002/ajh.27283 In Table 1, a typographical error was made in which the patient numbers and percentages
-
Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-07 Kevin H. M. Kuo, Rachael F. Grace, Eduard J. van Beers, Wilma Barcellini, Andreas Glenthøj, Susanne Holzhauer, Vanessa Beynon, Susan Morris, Junlong Li, Erin Zagadailov, Parija Patel, Hanny Al‐Samkari
-
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-07 Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Yanjie He, Yuxing Hu, Honghao Zhang, Xiaoling Xie, Yuhua Li
Although CD19 chimeric antigen receptor (CAR) T-cell therapy has a favorable complete response (CR) rate ranging from 71% to 93% for adult patients with refractory or relapsed (r/r) B-cell acute lymphoblastic leukemia (B-ALL),1 its long-term efficacy remains poor, with a 31%–100% relapse rate, a median leukemia-free survival (LFS) of 6.1–11.6 months, and a median overall survival (OS) of 12.9–18.2 months
-
Unswitched memory B cell deficiency in children with sickle cell disease and response to pneumococcal polysaccharide vaccine Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-06 Venée N. Tubman, Daniel Maysonet, Norma Estrada, Tripti Halder, Lindsey Ramos, Sameera Bhamidipati, Alexandre F. Carisey, Charles G. Minard, Carl E. Allen
Early mortality in sickle cell disease (SCD) is attributed to increased infections due to loss of splenic function. Marginal zone B cells are important for initial opsonization of pathogens and can be absent in spleen histopathology in SCD. The frequency of unswitched memory B cells (UMBC), the circulating correlate of marginal zone B cells, reflects the immunologic function of the spleen. We hypothesized
-
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-05-03 Kellie J. Archer, Han Fu, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Klaus H. Metzeler, Tobias Herold, Ann-Kathrin Eisfeld
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk groups. Nevertheless, there remains heterogeneity with respect to relapse-free survival (RFS) within these genetic-risk groups. Our training set included 306 adults on Alliance for Clinical Trials
-
Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis Leukemia (IF 11.4) Pub Date : 2024-05-02 Jeremy Ramdial, Partow Kebriaei, Richard E. Champlin, Uday Popat, Katayoun Rezvani, Elizabeth J. Shpall, Rohtesh S. Mehta
-
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping Blood Cancer J. (IF 12.8) Pub Date : 2024-05-03 Ying S. Zou, Melanie Klausner, Jen Ghabrial, Victoria Stinnett, Patty Long, Laura Morsberger, Jaclyn B. Murry, Katie Beierl, Christopher D. Gocke, Rena R. Xian, Kevin H. Toomer, Jing Christine Ye, Robert Z. Orlowski, Carol Ann Huff, Syed Abbas Ali, Philip H. Imus, Christian B. Gocke, Guilin Tang
-
Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-03 Sam Yuen, Tycel J. Phillips, Rajat Bannerji, Paula Marlton, Giuseppe Gritti, John F. Seymour, Anna Johnston, Christopher Arthur, Anna Dodero, Sunil Sharma, Jamie Hirata, Lisa Musick, Christopher R. Flowers
The Phase 2 portion of this study evaluated safety and efficacy of polatuzumab vedotin 1.8 mg/kg and venetoclax 800 mg, plus fixed‐dose obinutuzumab 1000 mg or rituximab 375 mg/m2 in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or diffuse large B‐cell lymphoma (DLBCL), respectively. Patients with complete response (CR) or partial response (PR)/stable disease (FL) or CR/PR (DLBCL)
-
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Blood Cancer J. (IF 12.8) Pub Date : 2024-05-02 Mazyar Shadman, Alessandra Tedeschi, Leyla Mohseninejad, Keri Yang, Nicole Lamanna, Sheng Xu, Aileen Cohen, Swetha Challagulla, Mei Xue, Rhys Williams, Susan M. O’Brien, Jennifer R. Brown, Constantine Tam
-
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target Blood Cancer J. (IF 12.8) Pub Date : 2024-05-02 Cèlia Dobaño-López, Juan García Valero, Ferran Araujo-Ayala, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Fabian Arenas, Marta Grau, Cristina López, Irene López-Oreja, Neus Serrat, Ares Martínez-Farran, Lluís Hernández, Heribert Playa-Albinyana, Rubén Giménez, Silvia Beà, Elías Campo, Jean-Michel Lagarde, Armando López-Guillermo, Laura Magnano, Dolors
-
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients Blood Cancer J. (IF 12.8) Pub Date : 2024-05-02 Ann-Kristin Schmälter, Maud Ngoya, Jacques-Emmanuel Galimard, Ali Bazarbachi, Jürgen Finke, Nicolaus Kröger, Martin Bornhäuser, Matthias Stelljes, Friedrich Stölzel, Johanna Tischer, Thomas Schroeder, Peter Dreger, Igor-Wolfgang Blau, Bipin Savani, Sebastian Giebel, Jordi Esteve, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty
-
High prevalence of iron deficiency and socioeconomic disparities in laboratory screening of non‐pregnant females of reproductive age: A retrospective cohort study Am. J. Hematol. (IF 12.8) Pub Date : 2024-05-02 Sophia Wen, Rosane Nisenbaum, Angela C. Weyand, Grace H. Tang, Michael Auerbach, Michelle Sholzberg
Iron deficiency anemia (IDA) and non‐anemic iron deficiency (NAID) are highly prevalent among non‐pregnant females of reproductive age. Canada has no national screening guidelines for this population. Screening, when performed, is often with a complete blood count alone without ferritin or iron indices. The primary objective was to determine the prevalence of screening for NAID and IDA over a 3‐year
-
ChatGPT’s ability to generate realistic experimental images poses a new challenge to academic integrity J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-05-01 Lingxuan Zhu, Yancheng Lai, Weiming Mou, Haoran Zhang, Anqi Lin, Chang Qi, Tao Yang, Liling Xu, Jian Zhang, Peng Luo
The rapid advancements in large language models (LLMs) such as ChatGPT have raised concerns about their potential impact on academic integrity. While initial concerns focused on ChatGPT’s writing capabilities, recent updates have integrated DALL-E 3’s image generation features, extending the risks to visual evidence in biomedical research. Our tests revealed ChatGPT’s nearly barrier-free image generation
-
Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach Leukemia (IF 11.4) Pub Date : 2024-04-30 Ieuan G. Walker, James P. Roy, Georgina S. F. Anderson, Jose Guerrero Lopez, Michael A. Chapman
-
Clonal hematopoiesis–derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders Leukemia (IF 11.4) Pub Date : 2024-04-29 Hussein Awada, Carmelo Gurnari, Valeria Visconte, Arda Durmaz, Teodora Kuzmanovic, Hassan Awada, Zheng Jin Tu, James R. Cook, Brian J. Bolwell, Ronald Sobecks, Matt Kalaycio, David Bosler, Jaroslaw P. Maciejewski
-
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia Blood (IF 20.3) Pub Date : 2024-04-30 Eric Durot, Damien Roos-Weil, Adrien Chauchet, Justine Decroocq, Roberta Di Blasi, Thomas Gastinne, Hedi Bensaber, Morgane Cheminant, Caroline Jacquet, Stéphanie Guidez, François-Xavier Gros, Emmanuel Bachy, Arthur Coste, Pascale Cony-Makhoul, Steven P. Treon, Alain Delmer, Ran Reshef, Steven Le Gouill, Jorge J. Castillo, Roch Houot
Histologic transformation of Waldenström macroglobulinemia (HT-WM) carries a poor prognosis with standard treatments. Here, we report the first series of HT-WM treated with chimeric antigen receptor T cells showing a high efficacy and no unexpected toxicity.
-
Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry Am. J. Hematol. (IF 12.8) Pub Date : 2024-04-30 Pramod K. Mistry, Manisha Balwani, Joel Charrow, Jeremy Lorber, Claus Niederau, Jenny L. Carwile, Antonio Oliveira‐dos‐Santos, Maria Gabriela Perichon, Sefika Uslu Cil, Priya S. Kishnani
Gaucher disease type 1 (GD1) is known for phenotypic heterogeneity and varied natural history. Registrational clinical trials enrolled narrowly defined phenotypes, but greater diversity is encountered in clinical practice. We report real‐world outcomes with long‐term eliglustat treatment in adults with GD1 in the International Collaborative Gaucher Group Gaucher Registry. Among 5985 GD1 patients in
-
High risk of progression for chronic major organ complications of sickle cell disease in adolescents and young adults: A long‐term neonatal cohort study Am. J. Hematol. (IF 12.8) Pub Date : 2024-04-30 Marion Borgey, Isabelle Genty, Anoosha Habibi, Jean‐Benoit Arlet, Nathalie Dhedin, François Lionnet, Emmanuelle Bernit, Maryse Etienne Julan, Gylna Loko, Cécile Arnaud, Annie Kamdem, Serge Pissard, Eric Guémas, Clara Noizat, Corinne Pondarré
The implementation of newborn screening associated with comprehensive care has led to the transformation of sickle cell disease (SCD) from a fatal illness in children to a chronic disease with multiple organ dysfunctions and premature death in adults.1, 2 Organ injury begins during childhood, as a result of chronic hemolysis-related endothelial dysfunction and hypoxia triggered by repeated vaso-occlusive
-
Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-04-29 Svenja Kastellan, Reinhard Kalb, Bia Sajjad, Lisa J. McReynolds, Neelam Giri, David Samuel, Till Milde, Miriam Elbracht, Susanne Holzhauer, Marena R. Niewisch, Christian P. Kratz
Constitutional heterozygous pathogenic variants in genes coding for some components of the Fanconi anemia-BRCA signaling pathway, which repairs DNA interstrand crosslinks, represent risk factors for common cancers, including breast, ovarian, pancreatic and prostate cancer. A high cancer risk is also a main clinical feature in patients with Fanconi anemia (FA), a rare condition characterized by bone